Cloris Xue

Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

Paolo A. Ascierto, Daniil Stroyakovskiy, Helen Gogas et al. · The Lancet Oncology · 2022 · 104 citations

Pharmacy, Oncology, Pharmacotherapy +14

Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors

Johanna C. Bendell, Philippe L. Bédard, Yung‐Jue Bang et al. · Cancer Research · 2020 · 64 citations

Life Sciences, Immunology, Oncology +17

Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study

Sara A. Hurvitz, Aditya Bardia, Vanesa Quiroga et al. · The Lancet Oncology · 2023 · 35 citations · Full text

Medicine, Oncology, Pharmacology +17

Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.

Peter A. Fasching, Aditya Bardia, Vanesa Quiroga et al. · Journal of Clinical Oncology · 2022 · 31 citations

Medicine, Oncology, Pharmacology +17

First‐line atezolizumab monotherapy in patients with advanced <i>BRAF</i>^V600 wild‐type melanoma

Sérgio Jobim Azevedo, Andréia Cristina de Melo, Louise Roberts et al. · Pigment Cell & Melanoma Research · 2021 · 29 citations

Medicine, Oncology, Pharmacology +16